The global malaria diagnostics market size was valued at USD 800.57 million in 2025 and is projected to grow from USD 833.95 million in 2026 to USD 1,156.33 million by 2034, registering a CAGR of 4.17% during the forecast period (2026–2034). Middle East and Africa dominated the malaria diagnostics market with a market share of 71.40% in 2025.
Malaria diagnostic tests are technologies used to detect Plasmodium parasites, parasite antigens, or genetic material in blood samples. These solutions include rapid tests, microscopy, and molecular diagnostic methods, enabling healthcare professionals to identify infections and support treatment.
The malaria diagnostics market demand is driven by the emphasis on early detection and expansion of malaria control programs. Advances in rapid testing and molecular diagnostics, awareness of diagnosis, and healthcare infrastructure contribute to malaria diagnostics market growth.
Download a Free Sample To learn more about this report,
Increasing Adoption of Highly Sensitive Molecular Diagnostics
A key market trend stems from the growing adoption of highly sensitive molecular diagnostic technologies for malaria detection, particularly in settings where parasite levels are low. Conventional rapid diagnostic tests and microscopy can have limitations in detecting low-parasitemia and asymptomatic infections, increasing demand for PCR, LAMP, and other nucleic-acid-based methods. These technologies provide higher sensitivity and support malaria surveillance and elimination efforts by identifying infections that may otherwise remain undetected. For example, LAMP-based malaria diagnostic technologies are being used to enable sensitive parasite detection with relatively simple equipment in resource-limited settings.
Expansion of AI-enabled Digital Microscopy
AI-enabled systems can automate blood smear analysis, identify Plasmodium parasites, and support parasite density assessment, reducing dependence on highly skilled microscopists. This transition is helping improve diagnostic consistency and expand testing capabilities in regions facing shortages of trained laboratory personnel. For example, Noul’s miLab integrates automated blood-smear preparation, staining, imaging, and AI-based parasite analysis to support malaria diagnosis.
The malaria diagnostics market has substantial exposure to supply chain disruptions, particularly due to dependence on specialized raw materials, diagnostic reagents, test components, manufacturing capacity, and international procurement networks. Supply interruptions, logistics constraints, shortages of critical components, and fluctuations in transportation and procurement costs are reshaping the market ecosystem by affecting product availability, delivery timelines, inventory management, and procurement programs across malaria-endemic regions globally. The market is expected to follow a stair-step recovery, with gradual improvements as supply availability normalizes, manufacturers rebuild inventories, procurement channels stabilize, and regional production capacity expands.
The malaria diagnostics market forecasts sustained investments directed toward next-generation rapid diagnostic tests, digital test readers, ultrasensitive parasite detection, and data-enabled malaria surveillance technologies, with funders increasingly supporting tools that improve diagnostic accuracy and real-time disease mapping in low-resource settings.
Key Investment and Funding Activities for Malaria Diagnostics Market, 2025–2026
Gates Foundation
USD 0.75 Million
In June 2026, Broad Institute receive funds from the Gates Foundation for the development of pathogen genomic-data analysis pipelines for malaria and other public-health pathogens in Africa.
USD 2.31 Million
In March 2026, the Gates Foundation funded Sproxil for the development of a near-real-time malaria RDT positivity map using each diagnostic test as a digital surveillance data point.
USD 4.59 Million
In November 2025, Audere received funding from the Gates Foundation for the adoption of digital rapid diagnostic-test readers to improve malaria diagnostic data and quality of care in LMICs.
USD 0.50 Million
In November 2025, Wondfo Biotech received funding for improving access to affordable, high-sensitivity malaria diagnostic tools for public-health programs in African LMICs.
USD 0.20 Million
In October 2025, IIT Kanpur received funds fo the development of low-cost, miniaturized biosensors for malaria and neonatal-health diagnostics in low-resource settings.
GHIT Fund
USD 1.0 Million
In January 2025, the GHIT Fund was given to Ehime University, Nagasaki University, Universiti Malaysia Sabah for the development of ultrasensitive, robust malaria rapid diagnostic tests using de novo antigen binders.
USD 0.65 Million
In January 2025, the ZOO-RDT project received USD 0.65 million to validate a new biomarker and reagents for diagnosing acute zoonotic malaria in Southeast Asia.
Increasing Need for Species-Specific and Drug Resistance Detection and Expansion of Malaria Elimination and Active Case Detection Programs Drive the Market
The growing need to differentiate Plasmodium species and identify infections that may respond differently to antimalarial treatment is increasing demand for advanced malaria diagnostic technologies. Conventional rapid diagnostic tests primarily detect malaria antigens, while molecular and specialized diagnostic methods can provide more detailed information for difficult-to-diagnose or low-parasitemia infections. The spread of P. falciparum and P. vivax across different geographic regions is encouraging healthcare systems to adopt diagnostic approaches that support accurate species identification and treatment decisions. This growing emphasis on diagnostic precision is supporting demand for advanced malaria testing solutions and driving market growth.
The shift from routine passive diagnosis toward active case detection and elimination-focused screening is creating additional demand for malaria diagnostics in areas with declining transmission. As countries move closer to malaria elimination, health authorities need to identify asymptomatic, imported, and low-density infections that may otherwise remain undetected and contribute to continued transmission. This increases the need for repeated screening across high-risk communities, border regions, migrant populations, and outbreak-prone locations. For example, malaria elimination programs conduct targeted screening around identified cases and in high-risk communities to locate additional infections and interrupt transmission chains.
High Dependence on Imported Diagnostic Supplies and Species & Biomarkers Variability Restrain Market Expansion
Many malaria-endemic countries depend on international manufacturers and procurement programs for rapid diagnostic tests, reagents, microscopy supplies, and other diagnostic consumables. Disruptions in international procurement, transportation delays, funding changes, or shortages of key diagnostic products can affect the consistent availability of tests in local healthcare facilities. This is particularly challenging for national malaria programs that require continuous supplies for seasonal campaigns and routine case management.
The presence of different malaria species and variation in their detectable biomarkers makes it difficult for healthcare programs to use a single RDT format across all endemic settings. RDT selection may need to consider whether testing must detect P. falciparum, P. vivax, or non-falciparum infections, as well as which antigens are targeted by the test. This creates additional product-selection and procurement requirements for national malaria programs operating across regions with different parasite profiles.
Expansion of Molecular Surveillance for Antimalarial Drug Resistance and G6PD Testing Offer Growth Opportunities to Market Players
The increasing spread and monitoring of antimalarial drug resistance is creating opportunities for molecular diagnostic companies to provide tests that identify resistance-associated genetic markers alongside malaria infection. Molecular diagnostics can detect low-density infections and support genotyping and detection of drug-resistance mutations, making them valuable for national surveillance and malaria elimination programs. This creates opportunities for molecular diagnostic developers and specialized laboratories to provide PCR and sequencing-based surveillance solutions as countries strengthen resistance monitoring.
The wider use of 8-aminoquinoline medicines such as primaquine and tafenoquine for P. vivax radical cure is creating an opportunity for diagnostic companies to combine malaria detection with G6PD testing. G6PD deficiency can cause severe hemolysis when these medicines are used without appropriate assessment, increasing the need for reliable G6PD status before treatment. The WHO recommends G6PD testing before the use of tafenoquine and recommends testing to guide primaquine treatment in appropriate settings. This creates an opportunity for manufacturers to develop integrated malaria-plus-G6PD testing platforms for clinics and malaria programs.
Diagnostic Inaccuracy and High Sensitivity with Field Usability Challenges Market Growth
A key challenge for the malaria diagnostics market is maintaining consistent diagnostic performance across regions with different Plasmodium species, parasite densities, and antigen characteristics. The emergence of P. falciparum strains with pfhrp2/3 gene deletions can reduce the performance of HRP2-based rapid diagnostic tests, while low-density infections can remain difficult to detect using conventional methods. Diagnostic manufacturers therefore need to continuously validate products against changing parasite populations and geographic conditions, increasing development, surveillance, and quality-control requirements.
Molecular techniques can detect infections missed by microscopy and conventional RDTs, but they often require more equipment, controlled testing environments, and skilled personnel. Manufacturers therefore face difficulty in combining laboratory-level sensitivity with the simplicity and portability required for community-based testing. This creates a trade-off between diagnostic performance and scalability, particularly in elimination-focused programs.
The rapid diagnostic tests segment accounted for a share of 63.25% in 2025 due to antigen-based detection, room temperature storage, and minimal sample preparation, enabling quick malaria confirmation in decentralized settings. These characteristics support testing during community screening campaigns, seasonal outbreaks, and remote surveillance where laboratory infrastructure is limited.
The molecular diagnostic segment is expected to grow at a CAGR of around 3.53% during the forecast period due to submicroscopic infection detection, species-level identification, and parasite genotyping, improving diagnostic precision. These capabilities support malaria elimination programs and reference laboratories that require sensitive testing for low-density infections and detailed parasite characterization.
Request Customizationto receive a tailored report.
In 2025, test kits accounted for a share of 48.60% due to single use formats, integrated reagents, and standardized testing procedures, enabling efficient malaria screening across healthcare facilities. These features simplify deployment during high-volume testing campaigns and support consistent diagnostic availability across malaria-endemic regions.
The PCR kits segment is expected to grow at a CAGR of 4.25% during the forecast period, driven by multiplex detection, low parasitemia identification, and genetic marker analysis, enabling detailed malaria investigation. These capabilities increase utilization in reference laboratories for species confirmation, surveillance of difficult infections, and monitoring of parasite genetic characteristics.
The hospitals & clinics segment accounted for a share of 64.11% in 2025 due to routine patient testing, treatment-linked diagnosis, and severe malaria assessment, generating recurring diagnostic demand. These facilities require malaria testing across outpatient, inpatient, emergency, and maternal care settings where rapid confirmation influences clinical management.
The diagnostic centers segment is expected to grow at a CAGR of 4.07% during the forecast period, fueled by specialized microscopy, centralized testing workflows, and confirmatory testing capabilities, supporting complex malaria diagnosis.
Speak to an Analystto discuss market opportunities.
Middle East & Africa: Market Dominance Led by High Malaria Burden and Expansion of National Diagnostic Programs
The Middle East & Africa malaria diagnostics market accounted for the largest regional share of 81.40% in 2025, driven by substantial malaria burden, particularly across sub–Saharan Africa, along with continued expansion of national malaria control and elimination programs. High transmission levels, seasonal outbreaks, and the need for widespread case confirmation sustain demand for rapid diagnostic tests and microscopy.
The South Africa malaria diagnostics market was valued at USD 205.77 million in 2025, driven by high prevalence of P. falciparum, increasing need for quality-assured RDTs, and geographic variation in malaria transmission intensity. The presence of pfhrp2/3 gene deletions also creates demand for alternative-antigen diagnostic products in affected areas. Nigeria’s participation in malaria surveillance and elimination initiatives supports demand for diagnostic technologies capable of detecting changing parasite profiles and maintaining reliable case confirmation across diverse epidemiological zones.
The malaria diagnostics market in Egypt was valued at USD 120.03 million in 2025, supported by malaria-free certification, border screening, and prevention of imported case re-establishment. Free malaria diagnosis across the country and trained health personnel at border points further support demand for RDTs and confirmatory testing, while continued cross-border surveillance sustains specialized diagnostic requirements.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Diverse Malaria Epidemiology and Increasing Focus on Elimination and Cross-Border Surveillance
The Asia Pacific malaria diagnostics market is expected to grow at a CAGR of 8.40% during the forecast period, showcasing the fastest regional growth. Growth is supported by the region's diverse malaria epidemiology, with countries managing different Plasmodium species, transmission patterns, and elimination stages.
The China malaria diagnostics market was valued at USD 24.74 million in 2025, supported by the country’s malaria-free status and continued focus on preventing re-establishment through imported-case surveillance and border health screening. Healthcare authorities maintain diagnostic capacity to identify malaria among travelers and migrant populations arriving from endemic countries.
The India malaria diagnostics market was valued at USD 12.41 million in 2025, fueled by endemicity of P. falciparum and P. vivax, regional differences in transmission, and the need for species-specific treatment decisions. National elimination efforts also require intensified surveillance in low-transmission districts, supporting use of RDTs, microscopy, and more sensitive testing approaches for identifying residual infections.
The Japan malaria diagnostics market was valued at USD 14.71 million in 2025, supported by imported malaria surveillance, travel-related infections, and the need for rapid differential diagnosis in non-endemic settings. Japan records malaria primarily as an imported infection, making travel history an important component of diagnostic assessment.
The malaria diagnostics market competitive landscape is moderately consolidated, with competition concentrated among established in vitro diagnostics and healthcare companies specializing in rapid diagnostic tests, molecular diagnostics, and infectious disease testing. Leading players compete through improvements in diagnostic sensitivity, species detection, and test stability. Emerging players also focus on developing ultrasensitive, multiplex, and molecular testing solutions. The malaria diagnostics market ecosystem is shaped by WHO procurement standards, national malaria programs, and parasite variability.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
North America Autoimmune Disease Diagnostics Market Size, Share, by 2034
Europe Autoimmune Disease Diagnostics Market Size, 2034
LAMEA Genetic Testing Market Size, 2034
North America Genetic Testing Market Size, 2034
Europe Genetic Testing Market Size, 2034
Asia Pacific Genetic Testing Market Size, 2034
We are featured on:
sales@straitsresearch.com